NuvaRing: three weeks in, a ring-free week, clot risk and side effects
NuvaRing is a flexible vaginal ring that releases two hormones, etonogestrel and ethinylestradiol, to prevent pregnancy. You leave it in place for three weeks and then have a ring-free week, so there is no daily tablet to remember. This page explains how you insert and remove the ring, what to do if it slips out, the risk of blood clots the doctor weighs up and the side effects listed in the product information.
What NuvaRing contains and how it works
Each ring releases 0.120 mg of etonogestrel, a progestogen, and 0.015 mg of ethinylestradiol, an oestrogen, every 24 hours. This makes it a combined hormonal contraceptive, like the combined pill and the patch. According to the summary of product characteristics (SmPC, section 5.1), several mechanisms contribute to the contraceptive effect, the most important being that ovulation is stopped.
NuvaRing is intended for women of fertile age; its safety and efficacy were established in women aged 18 to 40 and have not been studied under 18 (sections 4.1 and 4.2). In the Medicines Authority register, NuvaRing (MA031/02201) is classified as a prescription-only medicine (POM), and so is Teyla, another ring with the same two hormones. The combined pill is described on our page about Yasmin and Yaz, the patch on our page about Evra, and all the methods are compared on our page about the contraceptive pill.
How you insert and remove the ring
You insert NuvaRing yourself. Choose a comfortable position, such as standing with one leg raised, squatting or lying down, squeeze the ring between your fingers and push it into the vagina until it feels comfortable. The exact position does not matter for the contraceptive effect, as the SmPC states (section 4.2). An applicator can be used instead of your fingers, where one is supplied.
The ring stays in continuously for 3 weeks. You remove it on the same weekday as you inserted it, at about the same time, by hooking your index finger under it or holding it between two fingers, and you put the used ring back in its sachet for disposal. After a ring-free week you insert a new ring. The withdrawal bleed usually starts 2 to 3 days after removal and may not have finished when the next ring is due.
Make a habit of feeling for the ring, before and after sex for example, to confirm that it is still there. NuvaRing can interfere with a diaphragm, a cervical cap or a female condom, so these are not used as back-up methods with the ring.
Starting NuvaRing or switching to it
If you have not used hormonal contraception in the previous cycle, you insert the first ring on the first day of your period. You can also start on days 2 to 5, but then you use a barrier method such as a condom as well for the first 7 days (SmPC, section 4.2).
If you are changing from a combined pill or a patch, you insert the ring at the latest on the day after the usual tablet-free, patch-free or inactive tablet interval of your previous method. From a progestogen-only pill you can switch on any day, from an implant or a hormonal coil on the day it is removed, and from an injection when the next one would be due; in each case you also use a barrier method for the first 7 days. After giving birth, the SmPC advises starting during the fourth week, with a barrier method for the first 7 days if you start later.
If the ring slips out or is left out too long
The ring can come out, for example if it was not inserted properly, while you remove a tampon, during sex or with severe or chronic constipation (SmPC, section 4.4). Under 3 hours out of the vagina does not reduce protection: rinse the ring with cool or lukewarm water, not hot, and reinsert it promptly, no later than 3 hours after it came out.
If it has been out, or may have been out, for more than 3 hours in the first or second week, put it back as soon as you remember and use a condom until the ring has been in continuously for 7 days. In the third week, throw that ring away and either insert a new one at once, which starts a new three-week period, or have a withdrawal bleed and insert a new ring no later than 7 days after the old one came out; the second option only applies if the ring was in continuously for the previous 7 days.
If the ring-free week lasted longer than 7 days, insert a new ring as soon as you remember and use a condom for the next 7 days; if you had sex during the ring-free interval, pregnancy should be considered. A ring left in for up to 4 weeks still protects, but after more than 4 weeks pregnancy should be ruled out before the next ring. If you do not know how long the ring was out, a pregnancy test is advised before you insert a new one.
Emergency contraception after a risk is a separate question for a pharmacist or a doctor, and timing matters. Emergency contraception is not part of our Contraception service.
Broken rings, storage and other practical points
On very rare occasions the ring has come apart during use, and vaginal injury linked with a broken ring has been reported. If this happens, remove the broken ring, insert a new one as soon as possible, use a condom for the next 7 days and contact a doctor, because pregnancy should be considered. Breakage has been reported with vaginal preparations such as antifungal, antibiotic and lubricant products, although the SmPC considers vaginal antifungals and spermicides unlikely to affect how well the ring works (sections 4.4 and 4.5). Tampons do not affect how the hormones are absorbed.
A prolapse of the cervix, a cystocele or rectocele, or severe or chronic constipation can make the ring hard to insert correctly or easier to lose. Very rarely the ring has been placed in the urethra by mistake, so symptoms of cystitis can be a reason to check its position, and very rarely it has stuck to the vaginal wall and had to be removed by a healthcare professional.
The pharmacy writes the dispensing date on the pack. The ring is inserted no later than 4 months after that date and before its expiry date, and is stored below 30 °C in the original package, protected from light and moisture (SmPC, section 6.4).
The risk of blood clots
Every combined hormonal contraceptive increases the risk of a clot in a vein (venous thromboembolism, VTE) compared with not using one. The SmPC estimates that about 2 in 10,000 women who do not use one and are not pregnant develop a VTE in a year, and about 6 in 10,000 using a pill with levonorgestrel. Studies comparing NuvaRing with levonorgestrel pills gave inconsistent results, which corresponds to between about 6 and 12 cases a year in 10,000 women using the ring (section 4.4). All these numbers are lower than the number expected in pregnancy or after giving birth, and VTE can be fatal in 1 to 2% of cases.
The first year of use carries the highest risk, and restarting after a pause of at least 4 weeks may raise it again. It increases with obesity (BMI over 30), age, particularly over 35, a sibling or parent who had a clot at a relatively young age, major surgery, an operation on the legs or pelvis, a long period of immobility, and the 6 weeks after giving birth. Long flights of more than 4 hours can add to the risk, especially with other risk factors.
Smoking, high blood pressure, migraine and diabetes also raise the risk of clots in arteries, such as heart attack and stroke. The SmPC advises women who want to use a combined method not to smoke, and women over 35 who continue to smoke to use a different method. Before planned surgery, the ring is stopped at least four weeks in advance and restarted two weeks after you are fully mobile again.
Who should not use NuvaRing
The SmPC lists these contraindications (section 4.3). If one of them appears for the first time while you use the ring, it is removed at once. Your history, your family history and your blood pressure are checked before you start, and pregnancy is ruled out (section 4.4).
- A clot in a vein now or in the past, such as deep vein thrombosis or pulmonary embolism, or a known inherited or acquired tendency to clotting.
- Major surgery with prolonged immobilisation, or several risk factors that together make clots likely.
- A heart attack, angina, stroke or transient ischaemic attack, now or in the past, or a known tendency to clots in arteries.
- Migraine with focal neurological symptoms (aura).
- Diabetes with damage to blood vessels, severe high blood pressure or a severe disorder of blood fats.
- Pancreatitis, now or in the past, linked with very high triglyceride levels.
- Severe liver disease, unless liver tests have returned to normal, or a liver tumour now or in the past.
- Cancer of the breast or genital organs that depends on sex hormones, known or suspected.
- Vaginal bleeding that has not been diagnosed.
- An allergy to the active substances or to any other ingredient of the ring.
- Use of the hepatitis C medicines ombitasvir/paritaprevir/ritonavir with dasabuvir, or glecaprevir/pibrentasvir.
Warning signs that need urgent help
If you notice any of the signs below, the SmPC advises seeking urgent medical attention and telling the healthcare professional that you use a combined hormonal contraceptive (section 4.4). In an emergency, call 112. A new migraine, or migraine that becomes more frequent or more severe while you use the ring, is a reason to contact a doctor promptly: the SmPC notes that it may be an early warning of a stroke and may be a reason to stop using the ring immediately.
- Swelling of one leg or foot, or along a vein in the leg, pain or tenderness in the leg, warmth or red or discoloured skin.
- Shortness of breath out of nowhere, quick breathing, coughing that comes on suddenly and may bring up blood, stabbing chest pain, marked dizziness, or a heartbeat that is fast or uneven.
- A face, arm or leg that suddenly goes numb or weak, often on one side only, sudden confusion, difficulty with speech, sight or walking, or a headache that is sudden, severe or does not go away.
- Pain, pressure or heaviness in the chest, arm or below the breastbone, sometimes spreading to the back, jaw or stomach, with sweating, nausea or breathlessness.
- Blurred vision without pain, or sudden loss of vision.
Mood changes and depression
Depressed mood and depression are well-known undesirable effects of hormonal contraceptives, and the SmPC lists depression as common with NuvaRing (sections 4.4 and 4.8). Depression can be serious and is a well-known risk factor for suicidal behaviour and suicide, the SmPC adds. Tell a doctor about any change in mood or signs of depression, even in the first weeks with the ring.
If thoughts of suicide or self-harm come, do not wait to ask for help. In an emergency, call 112. Supportline 179 (Appoġġ): 24/7, free from landlines and mobiles. Richmond Foundation helpline 1770: Monday to Friday 8 am to 8 pm, Saturday until 4 pm.
Medicines that interact with NuvaRing
Some medicines and herbal products speed up the breakdown of the hormones and can lead to breakthrough bleeding or contraceptive failure. The SmPC names phenytoin, phenobarbital, primidone, bosentan, carbamazepine, rifampicin, possibly oxcarbazepine, topiramate, felbamate and griseofulvin, some HIV medicines such as ritonavir and efavirenz, and St John's wort (section 4.5).
With a short course of one of these, you use a barrier method such as a male condom during the treatment and for 28 days after it, and if the treatment runs beyond the 3 weeks of a ring, the next ring goes in without the usual ring-free week. With long-term treatment, another reliable non-hormonal method is recommended. Hormonal contraceptives can also raise levels of ciclosporin and lower levels of lamotrigine. Give the doctor a full list of what you take, including herbal products and vaginal preparations.
Side effects in the summary of product characteristics
In the clinical trials, the side effects reported most often were headache, vaginal infections and vaginal discharge, each by 5 to 6% of women (SmPC, section 4.8). The table summarises the frequencies given in the SmPC. Irregular bleeding or spotting can occur; if it starts after previously regular cycles while you use the ring as directed, other causes need to be looked into.
Some women have no withdrawal bleed in the ring-free week. If the ring was used as directed, pregnancy is unlikely, but if it was not, or two bleeds are missed, pregnancy must be ruled out before you continue. Hormone-dependent tumours, such as liver tumours and breast cancer, have been reported in association with combined hormonal contraceptives.
| Frequency | Side effects listed for NuvaRing |
|---|---|
| Common (up to 1 in 10) | Vaginal infection, depression, reduced sex drive, headache, migraine, abdominal pain, nausea, acne, breast tenderness, genital itching, painful periods, pelvic pain, vaginal discharge, weight gain, discomfort from the ring, the ring coming out |
| Uncommon (up to 1 in 100) | Cystitis or other urinary infection, mood swings, dizziness, visual disturbance, hot flushes, bloating, diarrhoea, vomiting, constipation, hair loss, rash, itching, back pain, painful or frequent urination, absent periods, pain during sex, vaginal dryness, tiredness, raised blood pressure |
| Rare (up to 1 in 1000) | Clots in veins or arteries, breast discharge (galactorrhoea) |
| Frequency not known | Allergic reactions including anaphylaxis, chloasma, tissue overgrowth at the ring site, vaginal injury linked with a broken ring, discomfort of the partner's penis, such as irritation, rash or itching |
Pregnancy, breast-feeding and planning a pregnancy
NuvaRing is not used in pregnancy. If you become pregnant with the ring in place, it is removed (SmPC, section 4.6). Large studies of combined pills have shown no increased risk of birth defects in children of women who used them before pregnancy, or by mistake in early pregnancy.
Oestrogens may reduce the amount of breast milk and change its composition, so the SmPC generally does not recommend NuvaRing until you have completely weaned your baby. If you stop using the ring because you want to become pregnant, the SmPC suggests waiting for a natural period before trying to conceive, because it makes the due date easier to work out.
How a request for NuvaRing is assessed
You fill in a medical questionnaire about the medicine, your health and other medicines you take, and the doctor reviews it in writing, whether you are starting the ring, continuing with it or changing to it from another method. The doctor weighs the same risks as for a combined pill, may ask for a recent blood pressure reading, may suggest a different method or may decline. If the doctor has questions, they ask them in writing in the chat in your account, and you get an email to let you know. There is no video call, no phone call and no live chat.
For some conditions, and in some individual cases, it is advisable to see a doctor in person; the doctor may recommend this. New symptoms, above all the warning signs listed above, need a doctor who can examine you.
If the doctor issues a prescription, you receive it as a PDF by email. You print it and bring it on paper to a pharmacy in Malta together with photo identification. Your prescription is issued in the standard EU cross-border format set out in Directive 2012/52/EU. A pharmacy in Malta may dispense it; the decision rests with the pharmacist. Take the prescription to a pharmacy within six months of the date on it; a prescription for an antibiotic cannot be dispensed more than ten days after its date of issue.
What does it cost?
Two amounts are separate here. The button on this page shows the fee for the doctor's review under our Contraception service, and the ring itself is paid for at the pharmacy, which sets the price. It is not an ePrescription and does not appear in myHealth; it is outside POYC and the Government Formulary List, and you pay for the medicine at the pharmacy in full.
The fee covers the medical consultation, not the issuing of a document. If the doctor declines on medical or legal grounds, we refund the fee. If the doctor asks you for documents, you have at least 7 days to send them in and we send you a reminder; if you ask us, we agree a longer deadline. If the case still cannot be completed, we close the request, let you know and refund the fee in full.
Who reviews your request?
Your request is reviewed by Damian Wojno, a doctor registered with the Polish Medical Chamber, licence no. 3211301. The doctor is not registered with the Medical Council of Malta.
Is NuvaRing prescription-only in Malta?
NuvaRing (MA031/02201) is classified as a prescription-only medicine (POM) in the Medicines Authority register, as is Teyla, another ring with the same hormones. Before a combined method is started, the doctor weighs your risk of clots, your blood pressure and the other medicines you take.
How long do you leave NuvaRing in?
Three weeks without a break. You then remove it on the same weekday as you inserted it, have a ring-free week in which a withdrawal bleed usually comes, and insert a new ring. A ring left in for up to 4 weeks still protects, but after more than 4 weeks pregnancy should be ruled out before you insert the next one.
What should I do if NuvaRing falls out?
If it has been out for less than 3 hours, rinse it in cool to lukewarm water and put it back within 3 hours; protection is not reduced. If it was out for longer, what you do depends on whether it happened in the first, second or third week, and you usually need a condom for the next 7 days.
Can you have sex with NuvaRing in?
The ring stays in continuously for three weeks, including during sex. Because it can come out during intercourse, the SmPC advises checking that it is in place before and after sex. The effect on a male partner of absorbing the hormones through the penis has not been studied.
Can I use tampons with NuvaRing?
Tampons do not change how the hormones are absorbed. On rare occasions the ring can come out while you remove a tampon, so check that it is still in place afterwards and follow the advice for a ring that has slipped out if it is not.
Does NuvaRing protect against sexually transmitted infections?
No. Hormonal contraceptives do not protect against HIV or other sexually transmitted infections, and the ring is not a barrier method even though it sits in the vagina. A male condom reduces the risk of infection and can be used together with the ring.
How should NuvaRing be stored?
Store it below 30 °C in the original package, away from light and moisture. The pharmacy writes the dispensing date on the pack, and the ring is inserted no later than 4 months after that date and before the expiry date, whichever comes first.
- Medicines Authority: NuvaRing 0.120 mg/0.015 mg per 24 hours vaginal delivery system (MA031/02201), with summary of product characteristics and package leaflet
- Medicines Authority: prescription-only and non-prescription medicines
- Medicines Act (Cap. 458), Article 81 (legislation.mt)
- Prescription and Dispensing Requirements Rules (S.L. 458.49), rule 4 (legislation.mt)
- Commission Implementing Directive 2012/52/EU on the recognition of medical prescriptions issued in another Member State (EUR-Lex)